← Eichor
Study identifier: NCT05203250 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Longitudinal Registry Including Patients Treated With Heavy Particles

Condition: Cancer · Oncology · Radiation Exposure  ·  Sponsor: CNAO National Center of Oncological Hadrontherapy

PhaseN/A
Planned participants3000
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The purpose of this registry is to collect retrospective and prospective standardized data of patients treated with particle therapy, either with protons or carbon ions, at the National Center for Oncological Hadrontherapy (CNAO) based in Pavia. By keeping track of the patients treated, it will allow the investigators to periodically analyze and evaluate data collected of daily clinical activity. This will help gathering more information on the results of particle therapy and will provide the basis for in depth evaluation of patients' outcome with respect to the delivered treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Chiara Campo, PhD  ·  +39 0382078407  ·  campo@cnao.it

Cristina Bono  ·  +39 0382078613  ·  bono@cnao.it

Always discuss trial participation with your own doctor first.

Locations (1)

National Center for Oncological Hadrontherapy (CNAO)Pavia, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05203250